Markets:

Overview

News

Currencies

International

Treasuries

Vanguard Health Care ETF (NY:VHT)

315.78 -5.88 (-1.83%)

Streaming Delayed Price Updated: 11:06 AM EDT, Sep 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vanguard Health Care ETF

< Previous 1 2 3 4 5 Next >

Vanguard Health Care ETF vs Simplify Health Care ETF ↗

September 01, 2026

Vanguard offers broad exposure at 0.09% cost with 1.5% yield, while Simplify's active strategy returned 32.4% over one year but charges 0.51%.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ? ↗

August 25, 2026

VHT charges low fees and holds more than 400 stocks for broader diversification. IXJ's portfolio of 110 holdings includes international exposure -- but comes at a higher cost.

Via The Motley Fool

Topics ETFs

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗

August 08, 2026

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

Via The Motley Fool

Topics ETFs Economy

VHT vs. PBE: Which Health Care ETF Is the Better Buy? ↗

July 30, 2026

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost...

Via The Motley Fool

Topics ETFs

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗

July 28, 2026

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

Via The Motley Fool

Topics ETFs

Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ ↗

July 26, 2026

Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC? ↗

July 23, 2026

One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.

Via The Motley Fool

Topics ETFs

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT? ↗

July 23, 2026

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

Via The Motley Fool

Topics ETFs

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? ↗

July 22, 2026

IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost.

Via The Motley Fool

Topics ETFs

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026? ↗

July 22, 2026

PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure.

Via The Motley Fool

Topics ETFs

3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech ↗

July 15, 2026

With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.

Via The Motley Fool

Topics ETFs

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗

July 09, 2026

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Via The Motley Fool

Topics ETFs

Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up? ↗

July 04, 2026

Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.

Via The Motley Fool

Topics ETFs

Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy? ↗

June 18, 2026

Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals.

Via The Motley Fool

Topics ETFs

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street ↗

June 03, 2026

Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.

Via The Motley Fool

Topics ETFs Intellectual Property Stocks

Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors? ↗

June 02, 2026

Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact.

Via The Motley Fool

Topics ETFs

U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ ↗

June 01, 2026

The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S....

Via The Motley Fool

Topics ETFs Intellectual Property

VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗

May 28, 2026

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

Via The Motley Fool

Topics ETFs

3 ETFs That Historically Perform Well in the Final Weeks of May ↗

May 22, 2026

May's reputation isn't as bad as some investors think, and this mix of ETFs can get the job done as summer nears.

Via The Motley Fool

Topics ETFs

Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs ↗

May 21, 2026

It's tough to think of an industry with more staying power than healthcare.

Via The Motley Fool

Topics ETFs Retirement

3 Vanguard ETFs to Buy to Protect Your Portfolio From a Potential Stock Market Crash ↗

May 01, 2026

There are enough economic signals to think that a bear market could be a real risk, so it's time to think about ways to protect yourself.

Via The Motley Fool

Topics ETFs Economy

Should You Really Buy Stocks With the S&P 500 Near Its Record High? Historical Data Gives a Clear Answer. ↗

April 22, 2026

Avoiding the stock market at all-time highs has historically been a mistake.

Via The Motley Fool

Topics Bonds Economy Stocks

1 No-Brainer Healthcare Vanguard ETF to Buy Right Now for Less Than $1,000 ↗

April 13, 2026

Healthcare stocks have been laggards for a while now. The current economic slowdown and structural tailwinds make it much more attractive now.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

3 ETFs to Own if the U.S. Economy Slows in 2026 ↗

March 30, 2026

The U.S. economy is showing signs of slowing and recession risk is rising. Here's how to prepare your portfolio.

Via The Motley Fool

Topics Artificial Intelligence Bonds ETFs

Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF ↗

March 24, 2026

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.

Via The Motley Fool

Topics ETFs

Why Did CRMD Stock Tumble Over 11% Today? ↗

March 05, 2026

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16.

Via Stocktwits

Topics Artificial Intelligence

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗

March 05, 2026

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six...

Via Stocktwits

TLRY Stock Slumps 4%: What’s Driving The Selloff? ↗

March 02, 2026

Tilray said that it has acquired the BrewDog brand and related intellectual property, UK brewing operations and eleven strategic brewpubs in the United Kingdom and Ireland.

Via Stocktwits

Topics Cannabis Intellectual Property

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗

February 26, 2026

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Via Stocktwits

Topics Artificial Intelligence

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗

February 26, 2026

Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.

Via Stocktwits

Topics Artificial Intelligence

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.